



argenx to host inaugural R&D day and webcast on September 22, 2016

Breda, the Netherlands / Ghent, Belgium, 15 September 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host its inaugural R&D day on Thursday, September 22, 2016 from 9:00 a.m. -12:00 p.m. ET in New York City.

During the event, members of argenx management will present updates to the Company's pipeline of differentiated antibodies including ARGX-113 for severe autoimmune diseases and ARGX-110 for oncology indications.

Guest speakers will also present on the treatment landscape and unmet needs in selected argenx indications including;

- James Howard, Jr., M.D., Chief, Neuromuscular Disorders Section, University of North Carolina, Chapel Hill, North Carolina, USA
- Adrian Newland, M.D., Professor of Hematology, The Royal London Hospital, London, UK
- Owen O'Connor, MD, PhD, Director of the Center for Lymphoid Malignancies, Columbia University, New York, USA

A live webcast of the event will be available via this [link](#). The webcast will be archived following the event and available for download on the Company's website at www.argenx.com.

About argenx

argenx (ARGX) combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey. www.argenx.com

For further information, please contact:

Joke Comijn, Communications and Investor Relations Manager

+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@arGEN-X.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.